Rhode Island Patent of the Month – March 2024
EpiVax, Inc., an immunology technology company, is developing treatment regimes with regulatory t-cell epitopes to target immune-related disorders. Their innovative approach involves inducing regulatory T-cells to suppress immune responses in patients, offering new hope for conditions such as autoimmune diseases, allergies, and transplant-related disorders.
At the heart of this method lies a novel class of regulatory T-cell epitopes, referred to as “Tregitopes.” These Tregitopes, comprised of specific amino acid sequences, have shown remarkable efficacy in modulating the immune system’s response. By administering therapeutically effective amounts of Tregitope compositions to patients, EpiVax aims to harness the power of regulatory T-cells to dampen unwanted immune reactions.
The beauty of this approach lies in its specificity and precision. Unlike broad-based immune-depleting therapies that weaken the entire immune system, EpiVax’s method targets the underlying mechanisms of immune regulation, offering a more targeted and effective treatment option. This precision is crucial for minimizing side effects and maximizing therapeutic benefits.
The potential applications of EpiVax’s method are vast. From autoimmune diseases like type 1 diabetes and lupus to transplant-related disorders such as graft-versus-host disease, the ability to induce immune tolerance could transform the lives of millions of patients worldwide. Additionally, this method holds promise for mitigating allergic reactions, preventing immune rejection of biologic medicines, and combating immune responses to infectious diseases.
Central to EpiVax’s approach is the identification and utilization of regulatory T-cell epitopes contained within common proteins. These Tregitopes, carefully selected for their ability to activate regulatory T-cells, serve as the cornerstone of the therapeutic compositions developed by EpiVax. By leveraging these natural mechanisms of immune regulation, EpiVax aims to provide safer and more effective treatments for a wide range of immune-related disorders.
Are you developing new technology for an existing application? Did you know your development work could be eligible for the R&D Tax Credit and you can receive up to 14% back on your expenses? Even if your development isn’t successful your work may still qualify for R&D credits (i.e. you don’t need to have a patent to qualify). To find out more, please contact a Swanson Reed R&D Specialist today or check out our free online eligibility test.
Who We Are:
Swanson Reed is one of the U.S.’ largest Specialist R&D tax advisory firms. We manage all facets of the R&D tax credit program, from claim preparation and audit compliance to claim disputes.
Swanson Reed regularly hosts free webinars and provides free IRS CE and CPE credits for CPAs. For more information please visit us at www.swansonreed.com/webinars or contact your usual Swanson Reed representative.
